Where is the tablet?

Since a few months I see a distinct increase in web exposure of the so-called ‘tablet concept’: a thin, 9 inch in diameter computerlike device without keyboard, intended to be used as a replacement of reading books and magazines, and allegedly competing against the ever popular Netbooks. There is an increasing number of eBooks or eReaders introduced in the market and the buzz about Apple developing such device is heating up day by day. But what is this ‘tablet’, and how does it compare to the current portfolio of eReaders such as the Kindle?

I believe that a successful ‘next generation eReader’ (i.e. tablets/MediaPads or whatever it will be called) will be characterized by the following features:

  • Rich media experience. Thus inclusion of video, audio, pictures
  • Flat, no buttons. Have you ever seen a magazine with buttons?
  • Always connected. People want to subscribe to newspapers and get the latest news instantly.
  • Touch based. A lot of gestures to be learned
  • Disruptive for the printing industry. There we go again. First the music, now printing

If there is a party that can pull this off it might be Apple. Sources say that the device was finished but got stuck on negotiations with the service provider for the wireless connection. Rumour has it that Apple will introduce the device somewhere in the first half of next year.

What would be the business benefit for such a device? Will this be a step closer to a paperless office. I guess that all depends on the functionality and price of such a device. After all, in a business environment the tablet will compete more or less with a laptop or desktop computer (since most people are staring at their screen 6 hours a day anyway). For mobile workers or sales representatives however, this may be a dream come true. Imagine going to a customer and show your newest product in the tablet. No printed cheesy brochures, always up to date and immersed in rich media. And what about conferences? In pharma many conferences are organized for the Health Care Professional. It is known that Big Pharma spends big on these conferences, so why not invest in a tablet to include when participating at the congress? Put all clinical data on it, conference program, information about the venue, etcetera. And since they have the device anyway, why not let them subscribe to your valuable Clinical Data Channel, so that the newest data is pushed to the HCP automatically?

So many possibilities. Or am I too much in overdrive here…? Don’t think so. Have a look at the following video and just amaze yourself where the future is going.

Digital Pharma Congress 2009- Socially Challenged Pharma

exl

We all know Social Marketing is the Next Big Thing. Or at least, that’s what we are all saying to each other. Making each other believe that the era of the 4/5/6 P’s is finally over. And of course Big Pharma can not stay behind forever. In a relatively short period the content of pharma congresses has changed dramatically. Two years ago a typical pharma marketing congress dealt with eDetailing, brand management and CRM systems. Now it’s about communities, Twitter, authenticity and transparency. Finally.

 

 

It was the first attempt for EXL Pharma to enter the ‘Old World’ with their Digital Pharma congress. Already an established event in the States, they now found the time right to see whether the Europeans are like-minded in the exciting area of new/social/digital media in pharma. And it seems that they are not the only one, by the way. This year alone we have been contacted by two other congress organizations which are planning to enter this space as well. It’s an interesting area to be in right now, especially when you have a story to tell.

We just returned from Barcelona (raining for two days, bummer!) and we look back to -in our view- a succesful first event organized by EXL. Of course not all things were perfect, it usually isn’t – especially when you do it for the first time. But I have to admit that Jason Youner and Bryan Main did a good job in pulling this thing off. Kudos go to them.

Now, let’s dive a bit into the program. I won’t cover all presentations, only the ones which were truly remarkable for me. For the Twitter feed with all tweets during the conference I refer to the EXL website with the Cover It Live feed (or search Twitter with #digitalpharma)

Old skool
EXL’s Digital Pharma Europe was organized in Barcelona on March 30 and 31. See for the full program here. The morning of the first day was reserved for a workshop entitled ‘Successfully integrating Digital Media into the Overall Marketing Mix’. Sam Trujillo, Director of Marketing Women’s Health explained in a three hour session the view of Bayer Schering on the way to engage with digital media in the marketing mix. Apart from the fact that a workshop usually involves ‘working’ and we didn’t do more than just listening, I did not find his story appealing and at it’s place at this event. His story was mainly focussing on digital media (fair enough) but it looked like the process he was presenting very much described the traditional approach of pharma companies using media: to stay in control. Seriously, I just do not think that putting your commercials on YouTube will generate a lot of traffic towards your channels. Who on earth is going to watch voluntarely a commercial of a pharma company, including the usual fair balance BS? It’s just not the channel for that.

The rest of the day was reserved for more Social Media stuff. So did Jeff Hithcock from ‘Children With Diabetes‘ (CWD) a touching presentation on his social network for parents and children with diabetes. Once started as a virtual space he created for his daughter suffering from diabetes, now a huge online community for thousands of diabetes children. Recently J&J acquired CWD. It’s not clear to me however what’s in it for J&J.

Pharma going social
Another great presentation was from Heidi Youngkin, Executive Director Global Marketing at J&J. She held an informative and engaging talk on her ‘Social Media Adventures’ within J&J. Intruiging to see that a pharma company is already that advanced. No doubt the fact that J&J is a huge company with a lot of FMCG might help, but still. I’m sure that her guidelines will be used as a ‘golden standard’ and reference frame within more pharma companies (I saw a lot of people making notes, since her presentation was not available online). Interestingly J&J started slowly with a blog about the history of the company (nice and safe). After they gained sufficient experience with this new medium they introduced a blog more specifically targeted towards their end users and dealing with more complex subjects. Now they have entered the third stage, going beyond blogs such as participating in the beforementioned community CWD. During the rest of the  conference J&J was quoted and cited as ‘Best Practices’ on several occassions.

The first day finished by a lively panel discussion moderated by Len Starnes, Head of Digital Marketing & Sales General Medicine at Bayer Schering. The panel discussion covered the paradigm shift of web 2.0 in the pharma world. Or should we say how pharma lives in the past not using (some of) these technologies. Interestingly it turned out that the FDA was present as well. Silently sitting in the back of the room, observing how Big Pharma is struggling with this paradigm shift. It sure is a pitty they (or anybody else for that matter) didn’t take the opportunity to start the conversation. And where were the European authorities?

Doctors and communities
Len must have done a great deal with EXL 😉 because the next day he kicked-off the second day of the event with his presentation entitled ‘Healthcare Professionals’ Social Networks – The Beginning of the End of Pharma Marketing As We Know It’. We’ve met Len at several other congresses and it’s always good to listen to his vision on digital marketing within Big Pharma. This time he gave a sound overview of all possible social networks available for the HCP (Health Care Professional). Although a few big players (Sermo and MedScape) there is still room for niche players like Ozmosis for example. And what about Europe? Well, it seems that Doctors.net.uk and DocCheck Faces are the biggest players on our continent but they will soon face competition by the Powerhouse Sermo which intends to introduce here in the not so distant future. Main question of course is how Big Pharma can participate in these communities. Sermo has a partnership with Pfizer, so is this the way to go? Len was firm in his statement that the pharma industry should observe, research, engage and discuss, but under no circumstances should hard sell. He also did a small poll on LinkedIn which showed that 86% of his network believes that Social Networks will have an impact on pharma marketing within the near future.

Enterprise 2.0 and innovation in Pharma

My presentation was next, talking about the internal use of Social Media in the light of innovation in marketing services. I am always surprised to see that an entire industry just jumps on the bandwagon of using social media for external use and just forgets that they first have to deal with yet another -equally important- community: their employees. Why is it that I can’t find more about my colleagues in Outlook’s address book other than their name, telephone number and office number whereas when I check on Facebook and LinkedIn I can find half of their life? Why is it that even a New Media Specialist is blocked access to YouTube at the office because she ‘might watch YouTube videos all day long’? Get seriouss, executives. Wake up in a new world and embrace yourself for the entrance of the digital natives, people who are actually used to share information with each other (and are hence not afraid to lose their ‘power’ when they do). Or read this for a change. We want to create a common platform within our organization where employees can find our internal blog, wikis, podcasts and share ideas. And if that means that we have to pull-in some people screamin’ and kickin’, so it is. Change is never without some pain.

 

 

 

 

YouTube genius
Yet another great presentation was from Kevin Nalty, Marketing Director Dermatology at a large pharma company which name could not be revealed but starts with an ‘M’ and ends with ‘erck’. Besides his serious job he moonlights as an official YouTube Comedian. His website Willvideoforfood is described as ‘a blog for online video, advertising, viral marketing, consumer generated media and blatant self-promotion’. Don’t know if he really needs a site doing all this since he’s one of the top-10 most viewed YouTube comedians with more than 750 videos seen in excess of 60 million times. He even wrote an e-book ‘How To Become Popular On YouTube Without Any Talent’. Well, I don’t have to explain you that we 100% agree with his vision about the power of video in communication. What we do differ in opinion is that although content is still king, form is becoming more and more important. By that I mean that the basic elements of filming should be carried out well (e.g. sound, lightning, basic rules of camera movement). That doesn’t mean that I think one should make a slick commercial. Please don’t. Some ‘rough edges’ gives it most of the time a bit more genuine look. But I will skip videos where the sound quality is poor, even if they have a nice story to tell.

Now, online video is exploding: Pharma, wake up and start using it!

The last presentation was an overview of the possibilities Google has to offer big Pharma. Interesting in that respect is Google.org, a CSR initiative of Google helping the community with their innovative concepts.

A quick wrap up ended the Digital Pharma Congress in Barcelona. Main take home messages of the audience (well, from people who actually dared to shout it out loud):

p1000881

That last point was not put in by me, but most probably due to me…

The future
I think it was a good start for such an event. I hope that for next congresses dealing with this subjects participation of European authorities is paramount since they are the gatekeepers of communication possibilities within our industry. Compared to the US Europe is different in that respect, also because we (still) have many different local authorities which can play and are playing according to their rules. The market is changing, people are getting more informed. The question is which information they use in order to get informed, and to what respect the quality of information is improved if Pharma can participate in the discussion. Pharma on the other hand should take it’s responsibility too, by being open and transparent about their products and claims. Pharma is low on the trust-scale, time to open up and fix that. Looking to the people in the audience I have the feeling that Pharma is ready for it. Now authorities, give them the opportunity to do so.

Stay tuned, soon I will post my presentation including the video online.

Slideshow 2.0

See the clip first before reading further.

Imagine that you want to start a service, a service that already exists. Let’s say, slideshows. There are tonnes of programs available on the PC or Mac, and an equivalent number online. So how are you going to compete? How are you going to diversify? And more importantly, what will be the business model? That’s what the guys and girsl at Animoto were up against. They did have one thing in their advantage; they were all coming from the film industry so the knew a thing or two about how to present images.

Animoto says in their tagline: ‘The End of Slideshows’. And it’s true. Although I can make nice slideshows in iPhote, some people may even be able to make nice slideshows on a PC (just don’t mention teh word PP, please…) but they all kinda look dull. OK, Ken Burns effect is sort of cool and it makes your slideshow more vivid but it wears off once you have seen it too much.

Also, making a slideshow, eerrr, nice slideshow can be painstakingly cumbersome. Import a picture, set in and out points, edit the movement… It takes a few hours before you master it and have some result. If you want to make it really cool (like the one you just saw) just add a few hours more to the equation.

So, take an existing service and improve it considerably, How does Animoto tackle this? First, ease of use. I don’t know if you believe me, but making this slideshow took me about 10 minutes (including making coffee): uploading pictures, adding some text, choose a song, push a button, drink coffee. Animoto analyzes your images and your music (although they say they do that…) and based on the outcome they create a slideshow. Which brings me to the second point: they make a really, really cool slideshow. Well, in my opinion they did a pretty good job.

 

animoto

 

So what’s the business model? Very web 2.0-ish. You can create for free (yeah, free = good = web 2.0!) a 30 seconds clip. Just upload some pictures (or get them from your Flickr account) choose a song in their library (or upload your own) and push a button. In no time you have your 30 seconds photo-videoclip. But that’s just to wet your appetite.

Of course, 30 seconds is way too short and before you know it you see yourself buying credits to make a full-length videoclip, including the option to download the file. Costs? $3 per video or $30 for an annual subscription so you get unlimited slideshows. Expensive? Not in my view. And then the ease of use comes back. With a few clicks (and a PayPal account) you have bought your credits and off you go.

So taking an existing service with lots of available options on the marketplace, think it through carefully and pimp it up like hell. That’s how Animoto did, and that’s how you should be looking at services too.

The state of social media in pharma

Just read on Shwen’s blog, a recent post about an interview with Mark Senak, lawyer and author of the EyeOnFDA blog. He talks about the reasons why Big Pharma is not embracing New/Social Media yet and the importance of doing so. He touches some very nice examples of what pharma companies can do with video to inform patients:

  • Patient Education video
  • Tool in Risk Management (communicating the misuse of an application)
  • Demonstration video how to use applications
  • Corporate’s philantropy or Corporate Social Responsibility programs
  • Clinical trial recruitment or recruitment in general

We have been doing several of these examples ourselves, so it’s good to see we’re on the right track.

See the entire interview here.

Sandflies caught on tape

Meet Bob. Professor Bob.

Bob knows an awful lot about sandflies and a devastating disease these little mosquito-like creatures may carry: leishmaniasis. The disease is caused by a little parasite and the dog plays a significant role in the reproduction process of this parasite.

We went to see Bob in the south of France, to make a video-series about all things biting your dog.

In two days we shot 10 videos about several subjects related to parasites on your dog (hence the title of the concept will be ‘What’s biting my dog?’). Bob explained in clear and understandable terms the technical aspects of parasitology, a rather complicated subject. Bob did this in such an engaging way that we are confident that this series will be a hit.

Also for Bob this was new. “Finally, after so many years I have the ability to talk directly to dog owners”, Bob says. “We, the scientific community, is often accused of not being able to communicate clearly what we are doing. It all remains high level. With new technologies we can reach many people with so little effort”.

We had a great time in France, also thanks to the hospitality of Bob and his wife. The main production is done, up to the post production.



The production team with the host (left to right): Erik, Remco, Bob, René


Our videos premier in the Life Science Reporter

Proud to announce that our partnership with Jacob Fleming is providing them the possibility to show in-depth interviews with:

It sure is a privilege to have had the opportunity to talk to these people.

Check out the Life Science Reporter here (more interesting stuff in there)

%d bloggers like this: